Medical Editor: John P. Cunha, DO, FACOEP
What Is Releuko?
Releuko (filgrastim-ayow) is a leukocyte growth factor indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever; reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML); reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT); and reduce the incidence and duration of sequelae of severe neutropenia‚ (e.g., fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia.
Releuko is biosimilar to Neupogen (filgrastim).
What Are Side Effects of Releuko?
Side effects of Releuko include:
- shortness of breath,
- numbness, and
- hair loss.
Dosage for Releuko
The recommended starting dose of Releuko for patients with cancer receiving myelosuppressive chemotherapy or induction and/or consolidation chemotherapy for AML is 5 mcg/kg/day subcutaneous injection, short intravenous infusion (15 to 30 minutes), or continuous intravenous infusion.
The recommended dose of Releuko for patients with cancer undergoing bone marrow transplantation 10 mcg/kg/day given as an intravenous infusion no longer than 24 hours.
The recommended starting dose of Releuko for patients with congenital neutropenia is 6 mcg/kg subcutaneous injection twice daily.
The recommended starting dose of Releuko for patients with cyclic or idiopathic neutropenia is 5 mcg/kg subcutaneous injection daily.
Releuko In Children
Releuko prefilled syringe with BD UltraSafe Plus Passive Needle Guard may not accurately measure volumes less than 0.3 mL due to the needle spring mechanism design. Therefore, the direct administration of a volume less than 0.3 mL using Releuko prefilled syringe is not recommended due to the potential for dosing errors.
For direct administration of doses less than 0.3 mL (180 mcg) use Releuko single-dose vial.
The pharmacokinetics of filgrastim in pediatric patients after chemotherapy are similar to those in adults receiving the same weight-normalized doses, suggesting no age-related differences in the pharmacokinetics of filgrastim.
The safety and effectiveness of filgrastim have been established in pediatric patients with SCN.
What Drugs, Substances, or Supplements Interact with Releuko?
Releuko may interact with other medicines.
Tell your doctor all medications and supplements you use.
Releuko During Pregnancy and Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant before using Releuko; it is unknown if Releuko will harm a fetus. It is unknown if Releuko passes into breast milk. Consult your doctor before breastfeeding.
Our Releuko (filgrastim-ayow) Injection, for Subcutaneous or Intravenous Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The following serious adverse reactions are discussed in greater detail in other sections of the labeling:
- Splenic Rupture [see WARNINGS AND PRECAUTIONS]
- Acute Respiratory Distress Syndrome [see WARNINGS AND PRECAUTIONS]
- Serious Allergic Reactions [see WARNINGS AND PRECAUTIONS]
- Sickle Cell Disorders [see WARNINGS AND PRECAUTIONS]
- Glomerulonephritis [see WARNINGS AND PRECAUTIONS]
- Alveolar Hemorrhage and Hemoptysis [see WARNINGS AND PRECAUTIONS]
- Capillary Leak Syndrome [see WARNINGS AND PRECAUTIONS]
- Myelodysplastic Syndrome [see WARNINGS AND PRECAUTIONS]
- Acute Myeloid Leukemia [see WARNINGS AND PRECAUTIONS]
- Thrombocytopenia [see WARNINGS AND PRECAUTIONS]
- Leukocytosis [see WARNINGS AND PRECAUTIONS]
- Cutaneous Vasculitis [see WARNINGS AND PRECAUTIONS]
- Aortitis [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Adverse Reactions In Patients With Cancer Receiving Myelosuppressive Chemotherapy
The following adverse reaction data in Table 2 are from three randomized, placebo-controlled studies in patients with:
- small cell lung cancer receiving standard dose chemotherapy with cyclophosphamide‚ doxorubicin‚ and etoposide (Study 1)
- small cell lung cancer receiving ifosfamide, doxorubicin‚ and etoposide (Study 2), and
- non-Hodgkin’s lymphoma (NHL) receiving doxorubicin, cyclophosphamide, vindesine, bleomycin, methylprednisolone, and methotrexate (“ACVBP”) or mitoxantrone, ifosfamide, mitoguazone, teniposide, methotrexate, folinic acid, methylprednisolone, and methotrexate (“VIM3”) (Study 3).
A total of 451 patients were randomized to receive subcutaneous filgrastim 230 mcg/m2 (Study 1), 240 mcg/m2 (Study 2) or 4 or 5 mcg/kg/day (Study 3) (n = 294) or placebo (n = 157). The patients in these studies were median age 61 (range 29 to 78) years and 64% were male. The ethnicity was 95% Caucasian, 4% African American, and 1% Asian.
Table 2. Adverse Reactions in Patients with Cancer Receiving Myelosuppressive Chemotherapy (With ≥ 5% Higher Incidence in Filgrastim Compared to Placebo)
|System Organ Class
(N = 294)
(N = 157)
|Blood and lymphatic system disorders|
|General disorders and administration site conditions|
|Musculoskeletal and connective tissue disorders|
|Pain in extremity*||7%||3%|
|Nervous system disorders|
|Respiratory, thoracic and mediastinal disorders|
|Skin and subcutaneous tissue disorders|
|Blood lactate dehydrogenase Increased||6%||1%|
|Blood alkaline phosphatase increased||6%||1%|
|*Percent difference (Filgrastim – Placebo) was 4%.|
Adverse events with ≥ 5% higher incidence in filgrastim patients compared to placebo and associated with the sequelae of the underlying malignancy or cytotoxic chemotherapy delivered included anemia, constipation, diarrhea, oral pain, vomiting, asthenia, malaise, edema peripheral, hemoglobin decreased, decreased appetite, oropharyngeal pain, and alopecia.
Adverse Reactions In Patients With Acute Myeloid Leukemia
Adverse reaction data below are from a randomized, double-blind, placebo-controlled study in patients with AML (Study 4) who received an induction chemotherapy regimen of intravenous daunorubicin days 1, 2, and 3; cytosine arabinoside days 1 to 7; and etoposide days 1 to 5 and up to 3 additional courses of therapy (induction 2, and consolidation 1, 2) of intravenous daunorubicin, cytosine arabinoside, and etoposide. The safety population included 518 patients randomized to receive either 5 mcg/kg/day filgrastim (n = 257) or placebo (n = 261). The median age was 54 (range 16 to 89) years and 54% were male.
Adverse reactions with ≥ 2% higher incidence in filgrastim patients compared to placebo included epistaxis, back pain, pain in extremity, erythema, and rash maculo-papular.
Adverse events with ≥ 2% higher incidence in filgrastim patients compared to placebo and associated with the sequelae of the underlying malignancy or cytotoxic chemotherapy included diarrhea, constipation, and transfusion reaction.
Adverse Reactions In Patients With Cancer Undergoing Bone Marrow Transplantation
The following adverse reaction data are from one randomized, no treatment-controlled study in patients with acute lymphoblastic leukemia or lymphoblastic lymphoma receiving high-dose chemotherapy (cyclophosphamide or cytarabine, and melphalan) and total body irradiation (Study 5) and one randomized, no treatment-controlled study in patients with Hodgkin's disease (HD) and NHL undergoing high-dose chemotherapy and autologous bone marrow transplantation (Study 6). Patients receiving autologous bone marrow transplantation only were included in the analysis. A total of 100 patients received either 30 mcg/kg/day as a 4-hour infusion (Study 5) or 10 mcg/kg/day or 30 mcg/kg/day as a 24-hour infusion (Study 6) filgrastim (n = 72), no treatment control or placebo (n = 28). The median age was 30 (range 15 to 57) years, 57% were male.
Adverse reactions with ≥ 5% higher incidence in filgrastim patients compared to patients receiving no filgrastim included rash and hypersensitivity.
Adverse reactions in patients receiving intensive chemotherapy followed by autologous BMT with ≥ 5% higher incidence in filgrastim patients compared to patients receiving no filgrastim included thrombocytopenia, anemia, hypertension, sepsis, bronchitis, and insomnia.
Adverse Reactions In Patients With Severe Chronic Neutropenia
The following adverse reaction data were identified in a randomized, controlled study in patients with SCN receiving filgrastim (Study 7). 123 patients were randomized to a 4-month observation period followed by subcutaneous filgrastim treatment or immediate subcutaneous filgrastim treatment. The median age was 12 years (range 7 months to 76 years) and 46% were male. The dosage of filgrastim was determined by the category of neutropenia.
Initial dosage of filgrastim:
- Idiopathic neutropenia: 3.6 mcg/kg/day
- Cyclic neutropenia: 6 mcg/kg/day
- Congenital neutropenia: 6 mcg/kg/day divided 2 times per day
The dosage was increased incrementally to 12 mcg/kg/day divided 2 times per day if there was no response.
Adverse reactions with ≥ 5% higher incidence in filgrastim patients compared to patients receiving no filgrastim included arthralgia, bone pain, back pain, muscle spasms, musculoskeletal pain, pain in extremity, splenomegaly, anemia, upper respiratory tract infection, and urinary tract infection (upper respiratory tract infection and urinary tract infection were higher in the filgrastim arm, total infection related events were lower in filgrastim treated patients), epistaxis, chest pain, diarrhea, hypoesthesia, and alopecia.
As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other filgrastim products may be misleading.
The incidence of antibody development in patients receiving filgrastim products has not been adequately determined. While available data suggest that a small proportion of patients developed binding antibodies to filgrastim products, the nature and specificity of these antibodies has not been adequately studied. In clinical studies using filgrastim, the incidence of antibodies binding to filgrastim was 3% (11/333). In these 11 patients, no evidence of a neutralizing response was observed using a cell-based bioassay.
Cytopenias resulting from an antibody response to exogenous growth factors have been reported on rare occasions in patients treated with other recombinant growth factors.
The following adverse reactions have been identified during post-approval use of filgrastim products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- splenic rupture and splenomegaly (enlarged spleen) [see WARNINGS AND PRECAUTIONS]
- acute respiratory distress syndrome [see WARNINGS AND PRECAUTIONS]
- anaphylaxis [see WARNINGS AND PRECAUTIONS]
- sickle cell disorders [see WARNINGS AND PRECAUTIONS]
- glomerulonephritis [see WARNINGS AND PRECAUTIONS]
- alveolar hemorrhage and hemoptysis [see WARNINGS AND PRECAUTIONS]
- capillary leak syndrome [see WARNINGS AND PRECAUTIONS]
- leukocytosis [seeWARNINGS AND PRECAUTIONS]
- cutaneous vasculitis [see WARNINGS AND PRECAUTIONS]
- Sweet’s syndrome (acute febrile neutrophilic dermatosis)
- decreased bone density and osteoporosis in pediatric patients receiving chronic treatment with filgrastim products
- myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with breast and lung cancer receiving chemotherapy and/or radiotherapy [see WARNINGS AND PRECAUTIONS]
- aortitis [see WARNINGS AND PRECAUTIONS]
No Information Provided
Read the entire FDA prescribing information for Releuko (Filgrastim-ayow Injection)
© Releuko Patient Information is supplied by Cerner Multum, Inc. and Releuko Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.
Health Solutions From Our Sponsors